4,6-Dichloro-N-methylpicolinamide

Catalog No. :
ACKJEZ419
CAS No. :
1379324-09-0
Molecular Formula :
C7H6Cl2N2O
Molecular Weight :
205.04

IUPAC Name:4,6-dichloro-N-methylpicolinamide

4,6-Dichloro-N-methylpicolinamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$67.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,6-Dichloro-N-methylpicolinamide
IUPAC Name4,6-dichloro-N-methylpicolinamide
MDL No.MFCD12965123
Molecular FormulaC7H6Cl2N2O
Molecular Weight205.04
SMILESO=C(C1=NC(Cl)=CC(Cl)=C1)NC
InChI KeyIJWIURVNWMGRII-UHFFFAOYSA-N
SynonymSorafenib Impurity HC121-201808;4,6-dichloro-N-methylpicolinamide;4,6-Dichloro-N-methyl-2-pyridinecarboxamide;Regorafenib Impurity 18;4,6-dichloro-N-methylpicolinamide? (Sorafenib Impurity);Regorafenib Impurity 18(Sorafenib Impurity 8);Regorafenib Impurity 44;2-Pyridinecarboxamide, 4,6-dichloro-N-methyl-
CAS No.1379324-09-0
PubChem CID129963725

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACKJEZ419 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACXLTJ136 route compound structure diagram
    ACXLTJ13688912-25-8 In Stock
  4. Then
  5. ACKJEZ419 route product structure diagram
    ACKJEZ4191379324-09-0
Inquiry

2. ACKJEZ419 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQFUC317 route compound structure diagram
    ACQFUC317873450-61-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKJEZ419 route product structure diagram
    ACKJEZ4191379324-09-0
Inquiry

Comments (0)